Merit Medical (MMSI) Upgraded to Buy: What Does It Mean for the Stock?
Merit Medical (MMSI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Merit Medical Q3 Earnings & Revenues Beat Estimate, Margins Expand
MMSI beats third-quarter 2025 estimates on strong revenue and margin growth, prompting a raised full-year outlook across segments.
Merit Medical Systems, Inc. (MMSI) Q3 2025 Earnings Call Transcript
Merit Medical Systems, Inc. ( MMSI ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Martha Aronson - President, CEO & Director Brian Lloyd - Chief Legal Officer & Corporate Secretary Raul Parra - CFO & Treasurer Conference Call Participants Jason Bednar - Piper Sandler & Co., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division John Young - Canaccord Genuity Corp., Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division James Sidoti - Sidoti & Company, LLC Presentation Operator Thank you for standing by, and welcome to the Merit Medical Systems Third Quarter 2025 Earnings Conference Call.
Merit Medical (MMSI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merit Medical (MMSI) Q3 Earnings and Revenues Surpass Estimates
Merit Medical (MMSI) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.86 per share a year ago.
MMSI or SAUHY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI) or Straumann Holding AG (SAUHY). But which of these two companies is the best option for those looking for undervalued stocks?
Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition
MMSI is set to acquire C2 CryoBalloon from Pentax for $22M, strengthening its GI portfolio. Despite near-term dilution, the deal positions Merit for long-term growth in gastroenterology.
Why Merit Medical (MMSI) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Merit Medical (MMSI) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Merit Medical Q2 Earnings Beat Estimates, Gross Margin Expands
MMSI beats second-quarter 2025 earnings estimates as gross margin expands and strong U.S. and Cardiovascular sales drive revenue growth.
